$12.77
1.028.68%
al cierre: -
$12.79
0.020.16%
After hour: 6:39 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
MoonLake Immunotherapeutics tiene un precio objetivo de consenso de $50.38 basado en las calificaciones de 14 analistas. El máximo es $104, emitido por Oppenheimer el junio 25, 2024. El mínimo es $5, emitido por Citigroup el octubre 29, 2025. Las 3 calificaciones de analistas más recientes fueron publicadas por HC Wainwright & Co., Citigroup y Guggenheim el noviembre 3, 2025, octubre 29, 2025 y septiembre 30, 2025, respectivamente. Con un precio objetivo promedio de $18.33 entre HC Wainwright & Co., Citigroup y Guggenheim, hay una 43.34% upside implícita para MoonLake Immunotherapeutics según estas calificaciones más recientes de analistas.
Firmas de analistas que realizan recomendaciones1
HC Wainwright & Co.
Citigroup
Guggenheim
Wedbush
Needham
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para MoonLake
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/03/2025 | 134.56% | HC Wainwright & Co. | → $30 | Upgrade | Neutral → Buy | |||
10/29/2025 | -60.91% | Citigroup | $5 → $5 | Downgrade | Neutral → Sell | |||
10/02/2025 | — | HC Wainwright & Co. | — | Downgrade | Buy → Neutral | |||
09/30/2025 | 56.37% | Guggenheim | $80 → $20 | Maintains | Buy | |||
09/30/2025 | 40.73% | Wedbush | $80 → $18 | Maintains | Outperform | |||
09/30/2025 | -60.91% | Citigroup | $72 → $5 | Downgrade | Buy → Neutral | |||
09/30/2025 | 56.37% | Needham | $66 → $20 | Maintains | Buy | |||
09/29/2025 | -21.81% | RBC Capital | $67 → $10 | Downgrade | Outperform → Sector Perform | |||
09/29/2025 | 564.58% | BTIG | $85 → $85 | Downgrade | Buy → Neutral | |||
08/06/2025 | 541.13% | Goldman Sachs | $74 → $82 | Maintains | Buy | |||
06/03/2025 | 423.85% | RBC Capital | $67 → $67 | Reiterates | Outperform → Outperform | |||
05/19/2025 | 376.94% | Wolfe Research | → $61 | Upgrade | Peer Perform → Outperform | |||
05/13/2025 | 416.03% | Needham | $66 → $66 | Reiterates | Buy → Buy | |||
04/30/2025 | 416.03% | Needham | $66 → $66 | Reiterates | Buy → Buy | |||
03/18/2025 | 423.85% | RBC Capital | → $67 | Initiates | → Outperform | |||
02/27/2025 | 470.76% | Goldman Sachs | $82 → $73 | Maintains | Buy | |||
02/27/2025 | 681.86% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
02/27/2025 | 416.03% | Needham | $62 → $66 | Maintains | Buy | |||
01/17/2025 | 541.13% | Goldman Sachs | $62 → $82 | Upgrade | Neutral → Buy | |||
01/10/2025 | 681.86% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
11/14/2024 | 681.86% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
11/08/2024 | 681.86% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
11/05/2024 | 470.76% | Wedbush | $92 → $73 | Assumes | Outperform → Outperform | |||
10/15/2024 | 681.86% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
09/23/2024 | — | Cantor Fitzgerald | — | Reiterates | → Overweight | |||
09/12/2024 | 681.86% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
09/12/2024 | 384.75% | Needham | $62 → $62 | Reiterates | Buy → Buy | |||
09/09/2024 | — | Cantor Fitzgerald | — | Reiterates | → Overweight | |||
08/26/2024 | — | Wolfe Research | — | Downgrade | Outperform → Peer Perform | |||
08/08/2024 | 384.75% | Needham | $66 → $62 | Maintains | Buy | |||
07/01/2024 | 681.86% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
06/25/2024 | 713.14% | Oppenheimer | → $104 | Initiates | → Outperform | |||
06/11/2024 | 681.86% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
06/10/2024 | 416.03% | Needham | $66 → $66 | Reiterates | Buy → Buy | |||
05/17/2024 | 681.86% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
05/08/2024 | 416.03% | Needham | $66 → $66 | Reiterates | Buy → Buy | |||
05/08/2024 | 681.86% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
04/23/2024 | 681.86% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
04/11/2024 | 681.86% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
04/09/2024 | 416.03% | Needham | $66 → $66 | Reiterates | Buy → Buy | |||
04/02/2024 | 384.75% | Goldman Sachs | → $62 | Initiates | → Neutral | |||
03/13/2024 | 619.31% | Wedbush | $92 → $92 | Reiterates | Outperform → Outperform | |||
03/11/2024 | 619.31% | Wedbush | $92 → $92 | Reiterates | Outperform → Outperform | |||
03/11/2024 | 416.03% | Needham | $66 → $66 | Reiterates | Buy → Buy | |||
03/11/2024 | 681.86% | HC Wainwright & Co. | $75 → $100 | Maintains | Buy | |||
03/04/2024 | 486.4% | HC Wainwright & Co. | $75 → $75 | Reiterates | Buy → Buy | |||
03/01/2024 | 619.31% | Wedbush | $92 → $92 | Reiterates | Outperform → Outperform | |||
03/01/2024 | 416.03% | Needham | → $66 | Reiterates | Buy → Buy | |||
02/15/2024 | — | Wolfe Research | — | Initiates | → Outperform | |||
12/18/2023 | 439.48% | Stifel | $66 → $69 | Maintains | Buy | |||
12/08/2023 | 462.94% | Citigroup | → $72 | Initiates | → Buy | |||
12/01/2023 | 619.31% | Wedbush | → $92 | Reiterates | Outperform → Outperform | |||
11/27/2023 | 486.4% | HC Wainwright & Co. | → $75 | Reiterates | Buy → Buy | |||
11/16/2023 | 619.31% | Wedbush | $86 → $92 | Maintains | Outperform | |||
11/15/2023 | 502.03% | Guggenheim | $70 → $77 | Maintains | Buy | |||
11/08/2023 | 509.85% | Cantor Fitzgerald | → $78 | Reiterates | Overweight → Overweight | |||
11/07/2023 | 572.4% | Wedbush | → $86 | Reiterates | Outperform → Outperform | |||
11/06/2023 | 572.4% | Wedbush | → $86 | Reiterates | Outperform → Outperform | |||
11/02/2023 | 478.58% | Stifel | → $74 | Initiates | → Buy | |||
10/16/2023 | 572.4% | Wedbush | → $86 | Reiterates | Outperform → Outperform | |||
10/16/2023 | 494.21% | Needham | → $76 | Reiterates | Buy → Buy | |||
10/03/2023 | 572.4% | Wedbush | → $86 | Reiterates | Outperform → Outperform | |||
09/18/2023 | 408.21% | Cantor Fitzgerald | → $65 | Reiterates | Overweight → Overweight | |||
09/18/2023 | 572.4% | Wedbush | → $86 | Reiterates | Outperform → Outperform | |||
09/14/2023 | 408.21% | Cantor Fitzgerald | → $65 | Reiterates | Overweight → Overweight | |||
09/12/2023 | 361.3% | Barclays | $41 → $59 | Maintains | Equal-Weight | |||
09/12/2023 | 408.21% | Cantor Fitzgerald | → $65 | Reiterates | Overweight → Overweight | |||
09/12/2023 | 486.4% | HC Wainwright & Co. | → $75 | Reiterates | Buy → Buy | |||
09/12/2023 | 494.21% | Needham | → $76 | Reiterates | Buy → Buy | |||
08/31/2023 | 494.21% | Needham | → $76 | Initiates | → Buy | |||
08/14/2023 | 572.4% | Wedbush | → $86 | Reiterates | Outperform → Outperform | |||
08/14/2023 | 486.4% | HC Wainwright & Co. | → $75 | Reiterates | Buy → Buy | |||
07/31/2023 | 572.4% | Wedbush | $61 → $86 | Maintains | Outperform | |||
07/26/2023 | 486.4% | HC Wainwright & Co. | → $75 | Reiterates | Buy → Buy | |||
07/17/2023 | 486.4% | HC Wainwright & Co. | $37 → $75 | Maintains | Buy | |||
07/03/2023 | 408.21% | Cantor Fitzgerald | $29 → $65 | Maintains | Overweight | |||
06/27/2023 | 220.56% | Barclays | $28 → $41 | Maintains | Equal-Weight | |||
06/26/2023 | 408.21% | Guggenheim | $51 → $65 | Maintains | Buy | |||
06/21/2023 | 189.29% | HC Wainwright & Co. | → $37 | Reiterates | Buy → Buy | |||
06/15/2023 | 118.92% | Barclays | → $28 | Initiates | → Equal-Weight | |||
05/15/2023 | 189.29% | HC Wainwright & Co. | → $37 | Reiterates | Buy → Buy | |||
05/10/2023 | 189.29% | HC Wainwright & Co. | $30 → $37 | Reiterates | → Buy | |||
05/04/2023 | 134.56% | HC Wainwright & Co. | → $30 | Reiterates | → Buy | |||
05/01/2023 | 298.75% | Guggenheim | → $51 | Initiates | → Buy | |||
04/20/2023 | 134.56% | HC Wainwright & Co. | $28 → $30 | Maintains | Buy | |||
03/22/2023 | 158.01% | Wedbush | → $33 | Initiates | → Outperform | |||
03/21/2023 | 118.92% | HC Wainwright & Co. | → $28 | Reiterates | → Buy | |||
03/20/2023 | 126.74% | Cantor Fitzgerald | $23 → $29 | Maintains | Overweight | |||
03/09/2023 | 181.47% | BTIG | → $36 | Initiates | → Buy | |||
03/06/2023 | 79.83% | Cantor Fitzgerald | → $23 | Reiterates | → Overweight | |||
02/14/2023 | 79.83% | Cantor Fitzgerald | → $23 | Initiates | → Overweight | |||
02/13/2023 | 118.92% | HC Wainwright & Co. | → $28 | Reiterates | → Buy | |||
02/03/2023 | 118.92% | HC Wainwright & Co. | → $28 | Reiterates | → Buy |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de MoonLake (MLTX)?
El último precio objetivo de MoonLake (NASDAQ:MLTX) fue comunicado por HC Wainwright & Co. el noviembre 3, 2025. La firma de analistas fijó un precio objetivo para $30.00 que espera MLTX a rise dentro de 12 meses (un posible 134.56% upside). 21 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre MoonLake (MLTX)?
La última calificación de analistas para MoonLake (NASDAQ:MLTX) fue proporcionada por HC Wainwright & Co., y MoonLake mejorado su buy calificación.
¿Cuándo se produjo la última revisión al alza de MoonLake (MLTX)?
La última revisión al alza de MoonLake Immunotherapeutics se produjo en noviembre 3, 2025, cuando HC Wainwright & Co. elevó su precio objetivo a $30. HC Wainwright & Co. anteriormente tenía a neutral para MoonLake Immunotherapeutics.
¿Cuándo fue la última revisión a la baja de MoonLake (MLTX)?
La última revisión a la baja de MoonLake Immunotherapeutics se produjo en octubre 29, 2025, cuando Citigroup cambió su precio objetivo de $5 a $5 para MoonLake Immunotherapeutics.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para MoonLake (MLTX)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de MoonLake, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de MoonLake se registró el noviembre 3, 2025, por lo que la próxima calificación estará disponible en torno al noviembre 3, 2026.
¿Es correcta la calificación de los analistas sobre MoonLake (MLTX)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de MoonLake (MLTX) fue un mejorado con un precio objetivo de $0.00 a $30.00. El precio actual al que cotiza MoonLake (MLTX) es de $12.79, que es within del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.